TM6SF2 and metabolic dysfunction-associated steatotic liver disease: The presence of certain genetic variants, such as single nucleotide polymorphisms in patatin-like phospholipase domain-containing protein 3 (PNPLA3), hydroxysteroid 17β dehydrogenase 13 (HSD17B13), or transmembrane 6 superfamily member 2 (TM6SF2) genes has also been associated with an increased risk of MASLD development, progression, and unfavorable prognosis [2], [3], [4].